CPTx

Executive Summary

CPTx is a Munich-based genetic medicines company founded in 2020, leveraging a proprietary immune-silent single-stranded DNA (ssDNA) platform to develop in vivo CAR-T and other gene therapies. The company aims to overcome the limitations of viral vectors and mRNA, focusing on accessibility and transformative potential. Although still in early private stages with no disclosed funding or pipeline, CPTx's approach could enable safer, more cost-effective treatments by eliminating the need for ex vivo cell manipulation. The platform's immune-silent design may reduce immunogenicity, broadening therapeutic windows. Given the innovative nature of its platform and the growing interest in non-viral gene therapy, CPTx represents a high-risk, high-reward opportunity in the genetics and genomics space.

Upcoming Catalysts (preview)

• Q3 2026Series A funding announcement70% success
• Q4 2026Lead program IND filing (in vivo CAR-T)40% success
• Q2 2027Partnership with large pharma for ssDNA platform50% success